Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JMS CoTSE:7702 +1.32%62 EBITDA Margin % is 5.58% as of Mar. 2026, which is 23% below its 10-year median of 7.25. GuruFocus rates TSE:7702 with a GF Score™ of 62/100 and a GF Value™ of 円469.13 (Fairly Valued). The stock has 10 warning signs investors should review. Among 815 Medical Devices & Instruments companies, JMS Co ranks worse than 53.25% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. JMS Co's EBITDA for the
six
months ended in Mar. 2026 was 円1,875 Mil. JMS Co's Revenue for the
six
months ended in Mar. 2026 was 円33,629 Mil. Therefore, JMS Co's EBITDA margin for the quarter that ended in Mar. 2026 was 5.58%.
JMS Co (TSE:7702) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
JMS Co EBITDA Margin % Related Terms
JMS Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for JMS Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7702 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, JMS Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JMS Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, JMS Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where JMS Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JMS Co (TSE:7702) has a EBITDA Margin % of 5.58% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on JMS Co and its competitors. This is 23% below median its historical median of 7.25. Over the past decade, JMS Co's EBITDA Margin % has ranged from 5.88 to 10.11. According to the industry distribution chart, JMS Co ranks #434 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 53.3%.
Is JMS Co's EBITDA Margin % too high?
JMS Co's current EBITDA Margin % of 5.58% is 23% below median its 10-year median of 7.25. Over the past 10 years, this metric has ranged from a low of 5.88 to a high of 10.11. The Medical Devices & Instruments industry median EBITDA Margin % is 7.52. JMS Co's value of 5.58% is 25.8% below this industry median. Based on the distribution chart, JMS Co ranks #434 out of 815 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, JMS Co has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does JMS Co's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, JMS Co ranks #434 out of 815 companies for EBITDA Margin %. This places JMS Co in the lower half of its industry. The industry median EBITDA Margin % is 7.52. JMS Co's value of 5.58% is 25.8% below this benchmark. Historically, JMS Co's own EBITDA Margin % has ranged from 5.88 to 10.11 over the past decade. While the company's 10-year median is 7.25 vs. the industry median of 7.52, JMS Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.52, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JMS Co's current EBITDA Margin % of 5.58% is 25.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on JMS Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JMS Co's current EBITDA Margin % is 5.58%, which is 23% below median its own 10-year median of 7.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JMS Co stock overvalued right now?
Based on GuruFocus' analysis, JMS Co (TSE:7702) is currently considered Fairly Valued. The stock's GF Value™ is 円469.13, compared to a current price of 円459.00 — trading 2.2% below its estimated fair value. The current EBITDA Margin % is 5.58%, which is 23% below median its 10-year median of 7.25 and 25.8% below the Medical Devices & Instruments industry median of 7.52. JMS Co's overall GF Score™ is 62/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For JMS Co (TSE:7702), the current EBITDA Margin % is 5.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JMS Co (TSE:7702) Overvalued in 2026?
Based on GuruFocus' analysis, JMS Co stock appears to be undervalued.
The current stock price of 円459.00 is trading 2.2% below its estimated GF Value™ of 円469.13.
GuruFocus considers JMS Co to be Fairly Valued.
Key valuation signals for TSE:7702:
EBITDA Margin %: 5.58% (23% below median its 10-year median of 7.25)
GF Value™: 円469.13 vs. price of 円459.00 (2.2% below fair value)
Industry Position: 25.8% below the Medical Devices & Instruments median (#434 of 815)
No single metric tells the full story. See the TSE:7702 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JMS Co Ltd is a Japan-based medical equipment manufacturer. The company is engaged in the manufacture, sale, export, and import of medical equipment and pharmaceuticals. Products offered by the company include an infusion pump, syringe pump, surgical gown, peritoneal dialysate, dialyzer, mask cap, sheet for treatment, pacemaker, heat exchanger, blood bag, among others. JMS has network operations in various countries including Europe, North America, Asia, the Middle East, Latin America and Africa.
62GF Score
Get the complete analysis for TSE:7702
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7702 has been successfully added to your 
